IFN-α2b Monotherapy in Patients with Chronic Hepatitis C and Persistently Normal or Near Normal Aminotransferase Activity: A Randomized, Controlled Study

To determine the effect of interferon-α2b (IFN-α2b) on the long-term suppression of hepatitis C virus (HCV) RNA in patients with persistently normal or near normal alanine aminotransferase (ALT) activity, 76 previously untreated patients with serum HCV RNA and ALT levels <1.5 times the upper limit of normal (ULN) were randomized to receive either interferon-α2b (IFN-α2b) 5 MU three times a week for 24 weeks (n = 37) or no treatment (n = 39). HCV RNA testing was performed at the end of treatment and after a 6-month follow-up period. Intention-to-treat analysis showed that HCV RNA was detected significantly less frequently in treated than in untreated patients, at the end of both treatment and follow-up (43.2% vs. 7.7%, p < 0.001, and 21.6% vs. 5.1%, p = 0.033, respectively). Among treated patients, sustained virologic response was significantly higher in non-1 than in genotype 1 patients (8 of 26 or 30.8% vs. 0 of 11, p = 0.038). According to multiple logistic regression, untreated patients had a 13.5 time...

[1]  A. Bisceglie.  Chronic hepatitis C viral infection in patients with normal serum alanine aminotransferases. , 1999 .

[2]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[3]  R. Ceriani,et al.  Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: A pilot randomized controlled study , 1998, Hepatology.

[4]  P. Marcellin,et al.  Therapy of hepatitis C: Patients with normal aminotransferase levels , 1997, Hepatology.

[5]  P. Simmonds,et al.  Interferon-alpha 2b therapy in low-activity hepatitis C: a pilot study. , 1997, Scandinavian journal of gastroenterology.

[6]  F. Callea,et al.  Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis , 1997, Hepatology.

[7]  L. Balart,et al.  Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. , 1997, The American journal of gastroenterology.

[8]  S. Gordon,et al.  Alfa interferon treatment of hepatitis C virus RNA-positive patients with normal or near-normal alanine aminotransferase levels. , 1997, The American journal of gastroenterology.

[9]  M. Mizokami,et al.  Interferon‐α therapy for individuals with normal serum alanine aminotransferase levels before treatment , 1997, Journal of gastroenterology and hepatology.

[10]  T. Hassanein,et al.  Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon α2b therapy , 1995 .

[11]  H. Conjeevaram,et al.  Volunteer Blood Donors with Antibody to Hepatitis C Virus: Clinical, Biochemical, Virologic, and Histologic Features , 1995, Annals of Internal Medicine.

[12]  M. Shindo,et al.  The virological and histological states of anti‐hepatitis C virus–positive subjects with normal liver biochemical values , 1995, Hepatology.

[13]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[14]  M. Alter,et al.  Epidemiology of Hepatitis C in the West , 1995, Seminars in liver disease.

[15]  T. Tsuji,et al.  Natural course of chronic hepatitis C. , 1993, The American journal of gastroenterology.

[16]  S. Baron,et al.  The interferons. Mechanisms of action and clinical applications. , 1991, JAMA.

[17]  J. Pawlotsky,et al.  Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. , 1996, Gastroenterology.